

Listing of the Claims

This listing of the claims will replace all prior versions and listings of claims in the application:

1. (Previously Presented) A method of facilitating vascular growth in cardiac muscle of a human subject in need of such treatment, comprising:
inhibiting activity of EMAP II of SEQ ID NO:4 in said human subject by administering an antibody that specifically binds to EMAP II of SEQ ID NO:4.
2. (Previously Presented) The method according to claim 1, wherein said antibody is administered in an amount effective to stimulate vascular growth in said cardiac muscle.
- 3-6. (Canceled)
7. (Previously Presented) The method according to claim 1, wherein said subject is afflicted with myocardial ischemia.
8. (Previously Presented) The method according to claim 1, wherein said subject is afflicted with atherosclerosis.
9. (Previously Presented) The method according to claim 1, wherein said subject is afflicted with a myocardial disease.
10. (Previously Presented) The method according to claim 9, wherein said myocardial disease is cardiomyopathy or cardiac hypertrophy.
11. (Previously Presented) A method of facilitating vascular growth in cardiac muscle tissue of a human subject in need of such treatment, said method comprising:

administering to said human subject an antibody that specifically binds to EMAP II of SEQ ID NO:4 in an amount effective to promote blood vessel formation in said cardiac muscle.

12-16. (Canceled)

17. (Previously Presented) The method according to claim 11, wherein said subject is afflicted with myocardial ischemia.

18. (Previously Presented) The method according to claim 11, wherein said subject is afflicted with atherosclerosis.

19. (Previously Presented) The method according to claim 11, wherein said subject is afflicted with a myocardial disease.

20-46. (Canceled)

47. (Previously Presented) The method of Claim 1, wherein the antibody is administered in a pharmaceutical formulation comprising the antibody that specifically binds to EMAP II of SEQ ID NO:4 and a pharmaceutically acceptable carrier.

48. (Previously Presented) The method of Claim 11, wherein the antibody is administered in a pharmaceutical formulation comprising the antibody that specifically binds to EMAP II of SEQ ID NO:4 and a pharmaceutically acceptable carrier.

49. (New) The method of Claim 1, wherein said antibody is a polyclonal, monoclonal or humanized antibody.

50. (New) The method of Claim 11, wherein said antibody is a polyclonal, monoclonal or humanized antibody.

51. (New) The method of Claim 1, wherein said administering step is carried out following a coronary artery occlusion in said subject.

52. (New) The method of Claim 11, wherein said administering step is carried out following a coronary artery occlusion in said subject.

53. (New) The method of Claim 1, wherein said administering step is carried out following a myocardial infarction in said subject.

54. (New) The method of Claim 11, wherein said administering step is carried out following a myocardial infarction in said subject.

55. (New) A method of facilitating vascular growth in cardiac muscle of a human subject in need of such treatment, said method comprising:

administering to said human subject an antibody that specifically binds to EMAP II of SEQ ID NO:1 in an amount effective to promote blood vessel formation in said cardiac muscle.

56. (New) The method of Claim 57, wherein the antibody is administered in a pharmaceutical formulation comprising the antibody that specifically binds to EMAP II of SEQ ID NO:1 and a pharmaceutically acceptable carrier.

57. (New) The method of Claim 57, wherein said antibody is a polyclonal, monoclonal or humanized antibody.